Mackie, Andrew

Andrew Mackie joined Imcyse in July 2020 focusing on Corporate Development and establishing industry partnerships. Prior to joining Imcyse, Andrew has held positions in Business Development, R&D and Investing at Biotech, Pharma and Venture Capital firms including Novartis, Sanofi, and Eli Lilly. Andrew has worked at a number of biotech companies, including Antisoma where he was Head of Clinical Development and Alliance Management and was CBO of Ergomed. Andrew holds a BSc in Biochemistry from Queen’s University in Canada, an LLB (Law) from the University of London and an MBA from the London Business School.